Abstract
AbstractDisseminated leishmaniasis (DL) is a distinct, severe, and emerging form of American tegumentary leishmaniasis. DL has been characterized by more than 10 multiple and pleomorphic cutaneous lesions, distributed in more than two noncontiguous parts of the body. Mucosal involvement is detected in up to 44% of cases. The development of the DL involves a complex and poorly understood network involving parasite, host immune response, and the environment, where L. braziliensis polymorphism plays a major role. A decrease in the type 1 immune response in the peripheral blood of DL patients appears to be caused by the attraction of Leishmania‐activated T cells to the multiple cutaneous lesions. DL is a difficult to cure disease and failure to pentavalent antimony therapy is observed in at least 60% of cases. Drug Dev Res 72:437–441, 2011. © 2011 Wiley‐Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
